{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:12:08Z","timestamp":1792145528036,"version":"4.4.0"},"reference-count":7,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2022,12,1]]},"abstract":"<jats:sec id=\"ab-des220001-1\"><jats:title>Clinical Question<\/jats:title><jats:p>What are the effects of systemic therapies for Stevens-Johnson syndrome\/toxic epidermal necrolysis (SJS\/TEN)?<\/jats:p><\/jats:sec><jats:sec id=\"ab-des220001-2\"><jats:title>Bottom Line<\/jats:title><jats:p>There is limited high-quality evidence to support the use of systemic immunomodulatory therapies to decrease mortality rates in SJS\/TEN.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamadermatol.2022.4543","type":"journal-article","created":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T15:01:41Z","timestamp":1666191701000},"page":"1436","source":"Crossref","is-referenced-by-count":10,"title":["Systemic Interventions for Treatment of Stevens-Johnson Syndrome\/Toxic Epidermal Necrolysis"],"prefix":"10.1001","volume":"158","author":[{"given":"Megan H.","family":"Noe","sequence":"first","affiliation":[{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G.","family":"Micheletti","sequence":"additional","affiliation":[{"name":"Departments of Dermatology and Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"12","key":"des220001r1","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1016\/j.jid.2020.03.968","article-title":"Incidence of epidermal necrolysis: results of the German Registry.","volume":"140","author":"Naegele","year":"2020","journal-title":"J Invest Dermatol"},{"issue":"6","key":"des220001r2","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/j.jid.2017.01.031","article-title":"The epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in the UK.","volume":"137","author":"Frey","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"12","key":"des220001r3","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/nm1208-1311","article-title":"Saving the skin from drug-induced detachment.","volume":"14","author":"Nickoloff","year":"2008","journal-title":"Nat Med"},{"issue":"2","key":"des220001r4","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jaad.2021.08.051","article-title":"Medical management of Stevens-Johnson syndrome\/toxic epidermal necrolysis among North American dermatologists.","volume":"87","author":"Han","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"des220001r5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013130.pub2","article-title":"Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS\/TEN overlap syndrome.","volume":"3","author":"Jacobsen","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"des220001r6","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jaad.2020.08.122","article-title":"Treating toxic epidermal necrolysis with systemic immunomodulating therapies: a systematic review and network meta-analysis.","volume":"84","author":"Tsai","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"des220001r7","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/jid.2012.510","article-title":"Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.","volume":"133","author":"Sekula","year":"2013","journal-title":"J Invest Dermatol"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2797539\/jamadermatology_noe_2022_es_220001_1670609124.35184.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T16:10:47Z","timestamp":1671639047000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2797539"}},"subtitle":["Summary of a Cochrane Review"],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":7,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2022.4543","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12,1]]}}}